Table 1.
Demographic and clinical characteristics
| Factor | Total (N = 19) |
|---|---|
| Age at IBD diagnosis, years | 26.7 ± 12.8 |
| Male gender | 10 (53) |
| Smoking | – |
| Past | 5 (26) |
| Never | 14 (74) |
| Family history of CRC | 3(16) |
| Family history of IBD | 6 (32) |
| Age at 1st visit after vedolizumab, years | 44.7±12.4 |
| IBD duration at first visit after vedolizumab, years | 13 [9, 25] |
| BMI at time of vedolizumab initiation, kg/m2 | 27.2 ± 6.4 |
| Autoimmune disease | 4 (21) |
| Prior surgical history | 5 (26) |
| Prior surgery type | |
| None | 14 (74) |
| Hernia repair | 2 (11) |
| Hernia repair + pouch redo | 1 (5) |
| Redo pouch | 1 (5) |
| Appendectomy | 1 (5) |
| Extra-intestinal manifestations | 9 (47) |
| Liver (primary sclerosing cholangitis) | 1 (5) |
| Joint | 6 (32) |
| Skin | 1 (5) |
| Eyes | 1 (5) |
| NSAIDs use | |
| Never | 9 (47) |
| Current | 3 (16) |
| Past | 7 (37) |
| Past cytomegalovirus infection | 1 (5) |
| Past Clostridium difficile of pouch | 5 (26) |
| Age at colectomy, years | 32.5 ± 11.7 |
| Pouch type | |
| J | 18 (95) |
| K/Barnett | 1 (5) |
Data presented as mean ± Standard deviation, median (P25, P75) or number (%).
IBD, inflammatory bowel disease; CRC, colorectal cancer; BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs.